VERTEX PHARMACEUTICALS INC / MA
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation MA
Business Address 50 NORTHERN AVENUE, BOSTON, MA, 02210
Mailing Address 50 NORTHERN AVENUE, BOSTON, MA, 02210
Phone 6173416393
Fiscal Year End 1231
EIN 043039129
Financial Overview
FY2025
$3.95B
Net Income
$25.64B
Total Assets
$17.58B
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
Annual Reports
10-K February 13, 2026
- Robust financial performance in 2025 with $10.75 billion in revenue, a 7.5% increase, and $4.2 billion in net income.
- Successful launch of Casgevy, a groundbreaking gene-editing therapy for sickle cell disease and beta-thalassemia, marking entry into gene therapy.
Insider Trading
STRONG SELL 7 insiders
24 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.